 NS3/4A serine protease is a prime target for direct-acting antiviral therapies against hepatitis<pathogen><disease><symptom> C<pathogen><disease> virus<pathogen> ( HCV<pathogen>) infection. Several NS3/4A inhibitors have been widely used in clinic , while new inhibitors with better characteristics are still urgently needed. GP205 is a new macrocyclic inhibitor of NS3/4A with low nanomolar activities against HCV<pathogen> replicons of genotypes 1b , 2a , 4a , and 5a , with EC